We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 30

SFDA’s working plan for the year of tiger
  • Sidley Austin LLP
  • China
  • February 16 2010

On January 19, 2010, officials from the State Food and Drug Administration (SFDA) and its local counterparts gathered together in Beijing to attend the 2010 National Conference on the Food and Drug Administration


New PRC Tort Law offers clarification on medical product liability, remains silent on top industry concerns
  • Sidley Austin LLP
  • China
  • January 29 2010

After eight years of deliberation and four rounds of revisions, the Tort Law of the People's Republic of China (the Tort Law) was adopted by the Standing Committee of the National People's Congress on December 26, 2009 and will become effective on July 1, 2010


China heightens crackdown on commercial bribery in pharmaceutical industry
  • Sidley Austin LLP
  • China
  • July 7 2010

On June 21, 2010, the Ministry of Health of China (MOH) published a notice in which it identifies key measures that local health authorities are required to take to crack down on commercial bribery in the pharmaceutical industry (the “Notice”


China promulgates new ADR reporting rules
  • Sidley Austin LLP
  • China
  • June 2 2011

On May 24, 2011, the Ministry of Health ("MOH") issued the revised Rules on Adverse Drug Reaction Reporting and Monitoring (the "Reporting Rules"), effective on July 1, 2011


China unveils draft regulations on labeling requirements for health foods
  • Sidley Austin LLP
  • China
  • June 7 2011

The State Food and Drug Administration ("SFDA") recently published an updated draft of the Rules on the Administration of Product Insert Sheets and Labels of Health Foods ("Draft Labeling Rules") for public comments


Chinese CDE launches joint review for chemical drug and API applications and other life sciences regulatory updates
  • Sidley Austin LLP
  • China
  • June 16 2011

The Center for Drug Evaluation (CDE) of the Chinese State Food and Drug Administration (SFDA) released a notice on June 7, 2011, establishing joint review for applications for chemical drugs and their active pharmaceutical ingredients (APIs) with a view to improving drug approval efficiency


China strengthening controls over human genetic resources
  • Sidley Austin LLP
  • China
  • June 21 2011

The Ministry of Science and Technology (“MOST”), the Ministry of Health (“MOH”) and the National Population and Family Planning Commission (“MPFPC”) of the Peoples Republic of China jointly issued a Notice Concerning the Protection and Administration of Human Genetic Resources (“HGR Notice”) on June 2, 2011


China SFDA imposes new regulatory requirements on cross-border pharmaceutical contract manufacturing activities
  • Sidley Austin LLP
  • China
  • August 15 2011

On July 22, 2011, the China State Food and Drug Administration (“SFDA”) published a notice on strengthening its supervision over domestic contract manufacturing activities for foreign pharmaceutical manufacturers (the “Notice”), with an aim to prevent export counterfeiting


China drug supply chain and GXP update
  • Sidley Austin LLP
  • China
  • January 4 2012

On December 23, 2011, the State Food and Drug Administration (SFDA) of China published the latest round of proposed revisions to the Drug Good Supply Practice Regulation (Draft GSP) for public comment by January 13, 2012


China issues five-year plan for pharmaceutical and medical device industries
  • Sidley Austin LLP
  • China
  • January 20 2012

On January 19, 2012, the Chinese Ministry of Industry & Information Technology issued the Twelfth Five-Year Plan (2011-2015) for the Development of Pharmaceutical and Medical Device Industries (the Plan